Incannex’s Psilocybin Targets Anxiety with Positive Topline Results
    Incannex’s Psilocybin Targets Anxiety with Positive Topline Results
    PRISM Biotech

    February 29, 2024 - by Catie Corcoran

    Incannex’s Psilocybin Targets Anxiety with Positive Topline Results

    29 February 2024

    New York, N.Y., February 29, 2024 - PRISM MarketView - Leading cannabinoid and psychedelic medicine biotechnology company, Incannex Healthcare (Nasdaq: IXHL), has achieved  positive topline results in its Phase 2 clinical trial of psilocybin in generalized anxiety disorder (GAD).
    Incannex Healthcare Limited - Prism MarketView

    Incannex Healthcare Limited - Prism MarketView

    Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine th

    Read More

    Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder - Prism MarketView

    Incannex HealthcareAppendix: Comparison of PsiGAD Treatments to Existing Registered Treatments for AnxietyFigure: meta-analysis(1) of psychotropic medications for GAD, as measured by the HAM-A; the best...

    Read More

    “This is the first time psilocybin has been investigated for treatment of generalized anxiety disorder, and the reduction in HAM-A scores we have observed are far greater than those reported from trials on established medicines for treatment of anxiety. The safety and efficacy results from PsiGAD1 implore us to continue the development of PsiGAD through large scale well-controlled trials, because this treatment method has the potential to improve the quality of life for millions of people suffering from generalized anxiety disorder.”

    Incannex President and CEO, Joel Latham

    Incannex is on track to submit an Investigational New Drug (IND) application with the FDA to proceed to a multi-site Phase 2b trial.
    Highlights
    Incannex’s trial met its primary endpoint, demonstrating a large clinical effect in the psilocybin treatment group over the placebo group.
    44% of patients in the psilocybin group demonstrated at least 50% reduction in anxiety score and 27% of patients showed disease remission, a remission rate more than 5 times higher than that of therapy with placebo.
    Psilocybin within the context of PsiGAD psychotherapy was observed to be well-tolerated, with only mild and moderate adverse events reported.
    GAD is characterized by excessive anxiety and worry that occurs more days than not for at least 6 months. People with GAD find it difficult to control their worry, which may cause significant distress and impairment in social, occupational, or other areas of functioning.
    About Incannex Healthcare Inc.
    Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.
    About PRISM MarketView:
    Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
    PRISM MarketView does not provide investment advice.
    Contact:
    PRISM MarketView
    info@prismmarketview.com
    646-863-6341
    Prism MarketView | Stock Market News & Investment Opportunities
    To see this content properly accept cookies.
    PRISM MarketView - Social Media (X)
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    Related Stories
    PRISM Biotech
    Capricor Therapeutics (CAPR) Trading Up Over 15% on Deal with Nippon Shinyaku to Expand Commercialization for Treatment of Duchenne Muscular Dystrophy

    New York, September 17, 2024 - PRISM MarketView - Capricor Therapeutics (CAPR) leads the PRISM Emerging Biotech Index today on the announcement that the company has signed a binding term sheet with Japanese pharmaceutical company, Nippon Shinyaku Co., Ltd. for the commer...

    17 September 2024

    PRISM Biotech
    New Tilray Medical Study on Medical Cannabis Highlights Reduced Pain and Improved Sleep for Fibromyalgia Patients

    New York, September 10, 2024 - PRISM MarketView - Tilray Medical, a division of Tilray Brands, Inc. (Nasdaq: TLRY) and a leading global player in the medical cannabis sector, recently released a new study, “Treatment in Pain Management and Other Fibromyalgia-Associated S...

    10 September 2024

    PRISM Biotech
    Veru Inc. (VERU) Advances Muscle Preservation Research with Enobosarm and Strengthens Financial Position

    New York, September 03, 2024 - PRISM MarketView - PRISM Emerging Weight Loss Index mover Veru Inc. (NASDAQ: VERU), is actively advancing its research and development efforts, particularly in its Phase 2b QUALITY clinical study for enobosarm—a drug designed to preserve mu...

    4 September 2024

    PRISM Biotech
    PRISM Weight Loss Index Leader LEXX Soars 24% on Positive DehydraTECH-Processed Rybelsus® Study Results

    New York, August 30, 2024 - PRISM MarketView - Lexaria Bioscience Corp. (NASDAQ: LEXX), today’s standout in the PRISM Weight Loss Index, saw its shares surge 24% following the announcement of promising results from its second human pilot study, GLP-1-H24-2. The study hig...

    30 August 2024

    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.